The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

With the development of genome sequencing, the role of molecular targeted therapy in
cancer is becoming increasingly important. However, genetic testing remains expensive …

Purpose: Somatic gene mutations have been increasingly recognized to impact prognosis
following resection of colorectal liver metastases (CLM). We aimed to determine the impact …

Studies have shown that the prevalence of RAS and BRAF mutations may differ by tumor
sidedness among metastatic colorectal cancer (mCRC) patients. Both mutation status and …

Cancers are the group of diseases, which arise because of the uncontrolled behavior of
some of the genes in our cells. There are possibilities of gene amplifications …

Background: Despite major advances in the management of metastatic colorectal cancer
(mCRC) with liver-only involvement, relapse rates are high and reliable prognostic markers …

Methods A search algorithm (Figure 1) based on a combination of the terms ''metastatic
colorectal cancer''AND “therapy” OR “treatment” AND “RAS” OR “KRAS” OR “NRAS” AND …

Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …

Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth
factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer …

Colorectal cancer (CRC), one of the leading causes of death among cancer patients, is a
heterogeneous disease and is characterized by diversions in multiple molecular pathways …